**Proteins** 



# **Product** Data Sheet

### **HJ445A**

Cat. No.: HY-163084 Molecular Formula:  $C_{24}H_{27}N_{7}O_{2}$ Molecular Weight: 445.52 Others Target:

Others Pathway:

Storage: Powder -20°C 3 years

4°C 2 years

In solvent -80°C 6 months

> -20°C 1 month

#### **SOLVENT & SOLUBILITY**

In Vitro

DMSO: 100 mg/mL (224.46 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.2446 mL	11.2228 mL	22.4457 mL
	5 mM	0.4489 mL	2.2446 mL	4.4891 mL
	10 mM	0.2245 mL	1.1223 mL	2.2446 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 2.5 mg/mL (5.61 mM); Clear solution; Need ultrasonic
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 2.5 mg/mL (5.61 mM); Clear solution; Need ultrasonic
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: 2.5 mg/mL (5.61 mM); Clear solution; Need ultrasonic

## **BIOLOGICAL ACTIVITY**

Description HJ445A is a potent MYOF inhibitor and binds to the MYOF-C2D domain with a  $K_D$  of 0.17  $\mu$ M. HJ445A potently repressed the proliferation of gastric cancer cells with IC $_{50}$  values of 0.16 and 0.14  $\mu$ M in MGC803 and MKN45, respectively. HJ445A

demonstrates superior antitumor efficacy in vivo and can be used for cancer research [1].

IC50: MYOF<sup>[1]</sup> IC<sub>50</sub> & Target

**REFERENCES** 

[1]. Haijun Gu, et al. Discovery of	f a Highly Potent and Selective MYOF	Inhibitor with Improved Wa	ter Solubility for the Treatment of Gastric Ca	ncer. J Med Chem. 2023 Dec 6
	Caution: Product has not been f	ully validated for medica	al applications. For research use only.	
		: 609-228-5909	E-mail: tech@MedChemExpress.com	
			Junction, NJ 08852, USA	
		, , , , , , , , , , , , , , , , , , , ,	, , , , , , , , , , , , , , , , , , , ,	

Page 2 of 2 www.MedChemExpress.com